Identifying Acute STEMI in the Presence of Paced Rhythm

EMS responds to a local coffee shop for a 77-year-old male who has reportedly fainted. While en route the call is upgraded to an unconscious patient and an engine company is dispatched for backup. On arrival the patient is conscious but lethargic. He appears acutely ill. The skin is pale and diaphoretic. His past medical history includes hypertension, dyslipidemia, myocardial infarction, a coronary artery bypass graft and heart failure. His current medications are aspirin, metoprolol, atorvastatin, lisinopril and furosemide. Upon further questioning he admits to chest discomfort. His OPQRST assessment is as follows: ≫ Onset: 15 minutes prior to EMS arrival; ≫ Provoke: Nothing makes the pain feel better or worse; ≫ Quality: Dull; ≫ Radiate: The pain does not radiate; ≫ Severity: 7/10; and ≫ Time: No previous episodes. His vital signs are a heart rate of 74, respiratory rate of 22, blood pressure of 116/67, oxygen saturation of 88% on room air and a temperature of 98.4 degrees F. The patient is relocated to the ambulance and undressed from the waist up. A well-healed surgical scar is noted from previous open-heart surgery as well as an implantable medical device in the upper-left chest. Other notable findings include jugular venous distention and breath sounds that reveal crackles in the lung bases. Figure 1: Initial rhythm Figure 2: Ventricular paced rhythm  
Source: JEMS Patient Care - Category: Emergency Medicine Authors: Tags: Case of the Month Special Topics Cardiac & Resuscitation Patient Care Source Type: news

Related Links:

This study is the first to provide a direct link between this inflammation and plaque development - by way of IFITM3. Scientists know that the production of IFITM3 starts in response to activation of the immune system by invading viruses and bacteria. These observations, combined with the new findings that IFITM3 directly contributes to plaque formation, suggest that viral and bacterial infections could increase the risk of Alzheimer's disease development. Indeed, researchers found that the level of IFITM3 in human brain samples correlated with levels of certain viral infections as well as with gamma-secretase activ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Cardiovascular disease (CVD) is the leading killer of both women and men in the US. Despite the significant impact CVD has on women, awareness and education for women’s heart disease has historically been low. A recent study, based on data from over two million patients, suggests that women were less likely to be prescribed aspirin, statins, and certain blood pressure medications compared to men. CVD is a group of diseases involving the heart or blood vessels. It includes high blood pressure (hypertension), coronary artery disease, heart attacks, heart failure, heart valve problems, and abnormal heart rhythms. CVD ca...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Drugs and Supplements Heart Health Women's Health Source Type: blogs
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received accelera...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ConclusionsA history of MST is common among older women veterans and associated with a range of medical and mental health diagnoses. These findings call attention to the need for additional research in this understudied population, and the importance of trauma-informed care approaches for women across the lifespan.
Source: Journal of General Internal Medicine - Category: Internal Medicine Source Type: research
The objective of this study was to determine the burden of 10 health conditions across race and ethnicity for a nationally-representative sample of aging Americans. Data from the 1998 to 2014 waves of the Health and Retirement Study, an ongoing longitudinal-panel study, were analyzed. Those aged over 50 years who identified as Black, Hispanic, or White were included. There were 5510 Blacks, 3423 Hispanics, and 21,168 Whites in the study. At each wave, participants reported if they had cancer, chronic obstructive pulmonary disease, congestive heart failure, diabetes, back pain, hypertension, a fractured hip, myocardial i...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
More News: Aspirin | Atorvastatin Calcium | Cardiology | Coronary Artery Bypass Graft | Emergency Medicine | Furosemide | Heart | Heart Attack | Heart Failure | Hypertension | Lipitor | Lisinopril | Medical Devices | Pain | Respiratory Medicine | Skin | Skin Graft | Statin Therapy | Toprol | Zivast